LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ONMD
OneMedNet Corporation
There isn't enough reported data to score ONMD yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ONMD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
ONMD's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ONMD PE Valuation
ONMD has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ONMD Forward outlook
There aren't enough analyst estimates for ONMD to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ONMD on earnings quality, reporting a profit while its opponent remains loss making.
ONMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.50 | -$0.20 |
| Q1 2026 | -$0.40 | +$3.10 |
| Q4 2025 | -$0.60 | +$3.20 |
| Q3 2025 | -$0.70 | +$48.80 |
| Q2 2025 | -$1.30 | +$48.70 |
ONMD is still losing money, but far less than before: $1.50 per share over the past year, against $50.00 at its worst in mid-2024.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ONMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ONMD on profitability, with a higher operating margin.
ONMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $292K | +88% |
| Q1 2026 | $96K | -30% |
| Q4 2025 | $891K | +3327% |
| Q3 2025 | $177K | +25% |
| Q2 2025 | $155K | -32% |
| Q1 2025 | $137K | -45% |
| Q4 2024 | $26K | -92% |
ONMD's revenue is growing: $292,000 last quarter, up 88% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -774% | +557 points |
| Q1 2026 | -2658% | -1035 points |
| Q4 2025 | -346% | +9908 points |
| Q3 2025 | -1263% | +418 points |
| Q2 2025 | -1331% | -250 points |
| Q1 2025 | -1623% | -776 points |
| Q4 2024 | -10254% | -8697 points |
| Q3 2024 | -1681% | N/A |
ONMD's operating margin was −774% last quarter, up 557 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ONMD on cash generation, producing positive trailing cash flow while its opponent burns cash.
ONMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.9M | +$403K |
| Q1 2026 | -$1.5M | +$409K |
| Q4 2025 | -$1.7M | +$344K |
| Q3 2025 | -$1.6M | +$354K |
| Q2 2025 | -$2.3M | -$780K |
| Q1 2025 | -$2M | -$400K |
| Q4 2024 | -$2.1M | +$1.9M |
| Q3 2024 | -$1.9M | -$1.8M |
ONMD has burned cash in almost every quarter: −$7M over the past year, against −$8M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ONMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ONMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.9% | +270K shares |
| 1 year | +51% | +2M shares |
| 3 years | +288% | +4.3M shares |
ONMD has 6M diluted shares, up 51% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2022 | — |
| Q2 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ONMD Net Leverage
ONMD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ONMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 29.2 | Neutral |
ONMD's weekly RSI is 45 (neutral) and its Stochastic is 29 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ONMD PE vs Healthcare Sector
ONMD has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ONMD on trend strength, trading above more of its moving averages.
ONMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.01 | 6.8% above |
| 20 week MA | $6.04 | 11% below |
| 50 week MA | $7.98 | 33% below |
| 100 week MA | $8.66 | 38% below |
| 200 week MA | $29.9 | 82% below |
ONMD has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 82% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ONMD on returns for 2026, with the stronger performance.
ONMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $99.4 | $101.0 | +1.6% |
| 2022 | $101.0 | $104.4 | +3.4% |
| 2023 | $104.4 | $8.10 | -92% |
| 2024 | $8.10 | $13.3 | +64% |
| 2025 | $13.3 | $12.7 | -4.5% |
| 2026 YTD | $12.7 | $5.35 | -58% |
ONMD is down 58% so far in 2026, after finishing higher in three of the previous five years.